Dermatopathology More Common in Crohn's Than Ulcerative Colitis

This article originally appeared here.
Share this content:
Dermatopathology More Common in Crohn's Than Ulcerative Colitis
Dermatopathology More Common in Crohn's Than Ulcerative Colitis

WEDNESDAY, Aug. 10, 2016 (HealthDay News) -- Cutaneous manifestations of inflammatory bowel disease (IBD) should be considered when reviewing unexplained skin lesions, particularly in patients with Crohn's disease (CD), according to research published online Aug. 6 in the Journal of Cutaneous Pathology.

Jennifer S. Ko, M.D., Ph.D., from the Cleveland Clinic Foundation, and colleagues cross referenced 4,147 classified IBD (Crohn disease [CD] or ulcerative colitis [UC]; 2000 to 2013) resections with skin biopsies. Biopsies were categorized by basic reaction pattern and neutrophilic versus granulomatous.

The researchers found that 133 patients had non-neoplastic skin biopsies (CD: 106 of 2,772 [3.7 percent]; UC: 27 of 1,375 [2.0 percent]). The most common biopsy results were miscellaneous (31.6 percent), nodular and diffuse dermal (21.8 percent), and spongiotic dermatitides (15.0 percent). CD cases showed a bias for spongiotic dermatitis, vasculitis, panniculitis, and infections, whereas UC bias was seen with psoriasiform, perivascular, nodular/diffuse dermal, and bullous categories, as well as neutrophilic processes. CD exclusively was associated with eukocytoclastic vasculitis, panniculitis, and pyoderma gangrenosum, while psoriasis vulgaris was exclusive to UC. Inverse psoriasis was seen for one CD patient.

"Our findings show the majority of dermatopathologic manifestations of IBD to have overlapping histology or pathophysiology to intestinal disease; with a wider spectrum of histologic patterns than typically discussed," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »